Brightwater is a UK medical research charity spun out of privately funded research. Our primary objective is to develop new treatments for Ewing Sarcoma. Ewing is a rare and particularly brutal form of cancer typically occurring during late childhood or early adolescence, however, it can develop later in life. Brightwater Research is in the late stages of developing a new drug to stop the spread of the cancer clone cells using our new drug ‘Valoxydin’. it does not reduce the primary tumour size whatsoever, but we believe it does shut down the cascade of genetic and biochemical events that make metastasis possible. Metastasis is the main cause of death in Ewing and the reason why so much surgery is employed. Without the cancer metastasizing, life expectancy should dramatically increase. In theory, this should extend life expectancy. Funded by the Trustees of the Charity, Brightwater is well equipped to do this research and is approaching the problem from the metastasis weakness in the cancer staging. At our own laboratory we have some very sophisticated facilities: we have organic synthetic chemistry including 400Mhz nuclear magnetic resonance spectrometry to make iterations of Valoxydin and a laboratory fully equipped for in vitro testing of the drug as we perform iterative modifications, including transcriptomic analysis. Animal model studies are outsourced and toxicity experiments are also undertaken by third party contract research organisations. We at Brightwater believe that our only ‘metric’ is the QUALY . We are entirely not-for-profit and if we are successful in the development of a new therapeutic approach to Ewing, it may very well be possible that other rare cancers can be treated using the same or similar drugs – one example is malignant nonseminoma, but there may be others. This is because there is an overlap in both current treatment regimens and gene expression sub-set data that makes it plausible that Valoxydin has wider applications.